{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:49:41Z","timestamp":1785527381090,"version":"3.56.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11864-026-01407-y","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:38:18Z","timestamp":1785321498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dedifferentiated Chondrosarcoma: Current Advances and Future Perspectives"],"prefix":"10.1007","volume":"27","author":[{"given":"Rebecca","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Vibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Moussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Faron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Verret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Zanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabih","family":"Mikhael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Tabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"L\u00e9vy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Honor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Le P\u00e9choux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratislav","family":"Bahleda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Le Cesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5579-5264","authenticated-orcid":false,"given":"Tarek","family":"Assi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"1407_CR1","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2217\/fon-2016-0226","volume":"13","author":"G Polychronidou","year":"2017","unstructured":"Polychronidou G, et al. Novel therapeutic approaches in chondrosarcoma. Future Oncol Lond Engl. 2017;13:637\u201348.","journal-title":"Future Oncol Lond Engl"},{"key":"1407_CR2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/CCO.0000000000000300","volume":"28","author":"FM Speetjens","year":"2016","unstructured":"Speetjens FM, de Jong Y, Gelderblom H, Bov\u00e9e JV. M. G. Molecular oncogenesis of chondrosarcoma: impact for targeted treatment. Curr Opin Oncol. 2016;28:314\u201322.","journal-title":"Curr Opin Oncol"},{"key":"1407_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/jso.24650","volume":"116","author":"PK Strotman","year":"2017","unstructured":"Strotman PK, Reif TJ, Kliethermes SA, Sandhu JK, Nystrom LM. Dedifferentiated chondrosarcoma: A survival analysis of 159 cases from the SEER database (2001\u20132011). J Surg Oncol. 2017;116:252\u20137.","journal-title":"J Surg Oncol"},{"key":"1407_CR4","first-page":"2506","volume":"12","author":"A Gazendam","year":"2023","unstructured":"Gazendam A, Popovic S, Parasu N, Ghert M, Chondrosarcoma. Clin Rev J Clin Med. 2023;12:2506.","journal-title":"Clin Rev J Clin Med"},{"key":"1407_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.32074\/1591-951X-213","volume":"113","author":"M Sbaraglia","year":"2020","unstructured":"Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. Pathologica. 2020;113:70\u201384.","journal-title":"Pathologica"},{"key":"1407_CR6","doi-asserted-by":"crossref","unstructured":"Chow WA. Chondrosarcoma: biology, genetics, and epigenetics. F1000Research. 2018;7:F1000 Faculty Rev-1826.","DOI":"10.12688\/f1000research.15953.1"},{"key":"1407_CR7","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ejca.2014.11.007","volume":"51","author":"AM Frezza","year":"2015","unstructured":"Frezza AM, et al. Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European musculoskeletal oncology society study. Eur J Cancer Oxf Engl. 2015;51:374\u201381.","journal-title":"Eur J Cancer Oxf Engl"},{"key":"1407_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/gcc.20937","volume":"51","author":"L Wang","year":"2012","unstructured":"Wang L, et al. Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosomes Cancer. 2012;51:127\u201339.","journal-title":"Genes Chromosomes Cancer"},{"key":"1407_CR9","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/gcc.21974","volume":"51","author":"D Meijer","year":"2012","unstructured":"Meijer D, et al. Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma. Genes Chromosomes Cancer. 2012;51:899\u2013909.","journal-title":"Genes Chromosomes Cancer"},{"key":"1407_CR10","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1046\/j.1365-2559.2001.01277.x","volume":"39","author":"YW Goh","year":"2001","unstructured":"Goh YW, et al. Extraskeletal myxoid chondrosarcoma: a light microscopic, immunohistochemical, ultrastructural and immuno-ultrastructural study indicating neuroendocrine differentiation. Histopathology. 2001;39:514\u201324.","journal-title":"Histopathology"},{"key":"1407_CR11","doi-asserted-by":"publisher","first-page":"100456","DOI":"10.1016\/j.jbo.2022.100456","volume":"37","author":"MR Gonzalez","year":"2022","unstructured":"Gonzalez MR, et al. Appendicular dedifferentiated chondrosarcoma: A management and survival study from the SEER database. J Bone Oncol. 2022;37:100456.","journal-title":"J Bone Oncol"},{"key":"1407_CR12","doi-asserted-by":"publisher","first-page":"35448","DOI":"10.52965\/001c.35448","volume":"14","author":"CA Gusho","year":"2022","unstructured":"Gusho CA, et al. Dedifferentiated Chondrosarcoma: A Case Series and Review of the Literature. Orthop Rev. 2022;14:35448.","journal-title":"Orthop Rev"},{"key":"1407_CR13","doi-asserted-by":"crossref","unstructured":"Miao R et al. Prognostic factors in dedifferentiated chondrosarcoma: A retrospective analysis of a large series treated at a single institution. Sarcoma. 2019;2019:9069272.","DOI":"10.1155\/2019\/9069272"},{"key":"1407_CR14","first-page":"e29105","volume":"14","author":"K Desai","year":"2022","unstructured":"Desai K, Liu S, Baskovich B, Makary RA. Case Report and Brief Literature Review on Dedifferentiated Chondrosarcoma in Proximal Phalanx: A Rare Location. Cureus. 2022;14:e29105.","journal-title":"Cureus"},{"key":"1407_CR15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/BF00941235","volume":"24","author":"M Mercuri","year":"1995","unstructured":"Mercuri M, Picci P, Campanacci L, Rulli E. Dedifferentiated chondrosarcoma. Skeletal Radiol. 1995;24:409\u201316.","journal-title":"Skeletal Radiol"},{"key":"1407_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1586\/14737159.2.5.461","volume":"2","author":"LB Rozeman","year":"2002","unstructured":"Rozeman LB, Hogendoorn PCW, Bov\u00e9e JVMG. Diagnosis and prognosis of chondrosarcoma of bone. Expert Rev Mol Diagn. 2002;2:461\u201372.","journal-title":"Expert Rev Mol Diagn"},{"key":"1407_CR17","doi-asserted-by":"publisher","first-page":"820254","DOI":"10.1155\/2012\/820254","volume":"2012","author":"S Malchenko","year":"2012","unstructured":"Malchenko S, et al. Putative multifunctional signature of lung metastases in dedifferentiated chondrosarcoma. Sarcoma. 2012;2012:820254.","journal-title":"Sarcoma"},{"key":"1407_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000325014","volume":"54","author":"E Estrada-Villase\u00f1or","year":"2010","unstructured":"Estrada-Villase\u00f1or E, Rico-Mart\u00ednez G, Linares-Gonzalez LM. Diagnosis of a dedifferentiated chondrosarcoma of the pelvis by fine needle aspiration. A case report. Acta Cytol. 2010;54:217\u201320.","journal-title":"Acta Cytol"},{"key":"1407_CR19","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","volume":"18","author":"CJ Pirozzi","year":"2021","unstructured":"Pirozzi CJ, Yan H. The implications of IDH mutations for cancer development and therapy. Nat Rev Clin Oncol. 2021;18:645\u201361.","journal-title":"Nat Rev Clin Oncol"},{"key":"1407_CR20","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.3390\/cancers16152752","volume":"16","author":"F Carosi","year":"2024","unstructured":"Carosi F, et al. Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives. Cancers. 2024;16:2752.","journal-title":"Cancers"},{"key":"1407_CR21","doi-asserted-by":"publisher","first-page":"979","DOI":"10.2217\/fon-2017-0523","volume":"14","author":"G Montalban-Bravo","year":"2018","unstructured":"Montalban-Bravo G, DiNardo CD. The role of IDH mutations in acute myeloid leukemia. Future Oncol Lond Engl. 2018;14:979\u201393.","journal-title":"Future Oncol Lond Engl"},{"key":"1407_CR22","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/ng.1004","volume":"43","author":"TC Pansuriya","year":"2011","unstructured":"Pansuriya TC, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet. 2011;43:1256\u201361.","journal-title":"Nat Genet"},{"key":"1407_CR23","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/path.2913","volume":"224","author":"MF Amary","year":"2011","unstructured":"Amary MF, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224:334\u201343.","journal-title":"J Pathol"},{"key":"1407_CR24","doi-asserted-by":"publisher","first-page":"e2400592","DOI":"10.1200\/PO-24-00592","volume":"9","author":"MJ Wagner","year":"2025","unstructured":"Wagner MJ, et al. Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic Targets. JCO Precis Oncol. 2025;9:e2400592.","journal-title":"JCO Precis Oncol"},{"key":"1407_CR25","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1158\/2767-9764.CRC-22-0397","volume":"3","author":"JKT Dermawan","year":"2023","unstructured":"Dermawan JKT, et al. Distinct IDH1\/2-associated Methylation Profile and Enrichment of TP53 and TERT Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma. Cancer Res Commun. 2023;3:431\u201343.","journal-title":"Cancer Res Commun"},{"key":"1407_CR26","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.3390\/jcm14093058","volume":"14","author":"J Swayambunathan","year":"2025","unstructured":"Swayambunathan J, Viza Gomes P, Childers-Qui\u00f1ones RV, Levine N, Visgauss J. IDH Mutations in Chondrosarcoma Correlate with Patient Survival in De-Differentiated but Not Conventional Subtypes. J Clin Med. 2025;14:3058.","journal-title":"J Clin Med"},{"key":"1407_CR27","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/(SICI)1096-9896(199912)189:4<454::AID-PATH467>3.0.CO;2-N","volume":"189","author":"JVMG Bov\u00e9e","year":"1999","unstructured":"Bov\u00e9e JVMG, et al. Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis. J Pathol. 1999;189:454\u201362.","journal-title":"J Pathol"},{"key":"1407_CR28","doi-asserted-by":"publisher","first-page":"100293","DOI":"10.1016\/j.jbo.2020.100293","volume":"22","author":"T Yang","year":"2020","unstructured":"Yang T, et al. Clonality analysis and IDH1 and IDH2 mutation detection in both components of dedifferentiated chondrosarcoma, implicated its monoclonal origin. J Bone Oncol. 2020;22:100293.","journal-title":"J Bone Oncol"},{"key":"1407_CR29","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.5858\/arpa.2020-0379-OA","volume":"145","author":"C-HG Lucas","year":"2021","unstructured":"Lucas C-HG, Grenert JP, Horvai A. Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma. Arch Pathol Lab Med. 2021;145:1009\u201317.","journal-title":"Arch Pathol Lab Med"},{"key":"1407_CR30","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41379-018-0140-5","volume":"32","author":"N Makise","year":"2019","unstructured":"Makise N, et al. H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features. Mod Pathol. 2019;32:435\u201345.","journal-title":"Mod Pathol"},{"key":"1407_CR31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/1097-0142(19950715)76:2<223::AID-CNCR2820760210>3.0.CO;2-4","volume":"76","author":"WW Simms","year":"1995","unstructured":"Simms WW, Ord\u00f3\u00f1ez NG, Johnston D, Ayala AG, Czerniak B. p53 expression in dedifferentiated chondrosarcoma. Cancer. 1995;76:223\u20137.","journal-title":"Cancer"},{"key":"1407_CR32","first-page":"51","volume":"7","author":"RM Terek","year":"1998","unstructured":"Terek RM, et al. p53 mutations in chondrosarcoma. Diagn Mol Pathol Am J Surg Pathol Part B. 1998;7:51\u20136.","journal-title":"Diagn Mol Pathol Am J Surg Pathol Part B"},{"key":"1407_CR33","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1002\/(SICI)1097-0142(19981201)83:11<2324::AID-CNCR12>3.0.CO;2-U","volume":"83","author":"Y Oshiro","year":"1998","unstructured":"Oshiro Y, et al. Altered p53 is associated with aggressive behavior of chondrosarcoma: a long term follow-up study. Cancer. 1998;83:2324\u201334.","journal-title":"Cancer"},{"key":"1407_CR34","doi-asserted-by":"publisher","first-page":"4844","DOI":"10.1158\/1078-0432.CCR-23-1703","volume":"29","author":"RA Denu","year":"2023","unstructured":"Denu RA, et al. Clinico-genomic profiling of conventional and dedifferentiated chondrosarcomas reveals TP53 mutation to be associated with worse outcomes. Clin Cancer Res Off J Am Assoc Cancer Res. 2023;29:4844\u201352.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1407_CR35","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/01.cco.0000129678.72521.e5","volume":"16","author":"AA Sandberg","year":"2004","unstructured":"Sandberg AA. Genetics of chondrosarcoma and related tumors. Curr Opin Oncol. 2004;16:342\u201354.","journal-title":"Curr Opin Oncol"},{"key":"1407_CR36","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41419-022-04916-4","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, Yang S, Liu Y, Yang S. Mice with Trp53 and Rb1 deficiency in chondrocytes spontaneously develop chondrosarcoma via overactivation of YAP signaling. Cell Death Dis. 2022;13:570.","journal-title":"Cell Death Dis"},{"key":"1407_CR37","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/ng.2668","volume":"45","author":"PS Tarpey","year":"2013","unstructured":"Tarpey PS, et al. Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nat Genet. 2013;45:923\u20136.","journal-title":"Nat Genet"},{"key":"1407_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00428-014-1685-4","volume":"466","author":"MF Amary","year":"2015","unstructured":"Amary MF, et al. Isocitrate dehydrogenase 1 mutations (IDH1) and p16\/CDKN2A copy number change in conventional chondrosarcomas. Virchows Arch Int J Pathol. 2015;466:217\u201322.","journal-title":"Virchows Arch Int J Pathol"},{"key":"1407_CR39","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.3390\/cancers13102390","volume":"13","author":"AE Zaj\u0105c","year":"2021","unstructured":"Zaj\u0105c AE, et al. Chondrosarcoma-from Molecular Pathology to Novel Therapies. Cancers. 2021;13:2390.","journal-title":"Cancers"},{"key":"1407_CR40","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1038\/s41467-019-12525-7","volume":"10","author":"R Nicolle","year":"2019","unstructured":"Nicolle R, et al. Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression. Nat Commun. 2019;10:4622.","journal-title":"Nat Commun"},{"key":"1407_CR41","doi-asserted-by":"publisher","first-page":"43557","DOI":"10.18632\/oncotarget.9618","volume":"7","author":"L Gao","year":"2016","unstructured":"Gao L, et al. Targeted next-generation sequencing of dedifferentiated chondrosarcoma in the skull base reveals combined TP53 and PTEN mutations with increased proliferation index, an implication for pathogenesis. Oncotarget. 2016;7:43557\u201369.","journal-title":"Oncotarget"},{"key":"1407_CR42","doi-asserted-by":"publisher","first-page":"262","DOI":"10.4103\/0019-5413.132506","volume":"48","author":"A Sakamoto","year":"2014","unstructured":"Sakamoto A. The molecular pathogenesis of dedifferentiated chondrosarcoma. Indian J Orthop. 2014;48:262\u20135.","journal-title":"Indian J Orthop"},{"key":"1407_CR43","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0165-4608(00)00335-6","volume":"124","author":"DP O\u2019Malley","year":"2001","unstructured":"O\u2019Malley DP, et al. Chromosomal changes in a dedifferentiated chondrosarcoma: a case report and review of the literature. Cancer Genet Cytogenet. 2001;124:105\u201311.","journal-title":"Cancer Genet Cytogenet"},{"key":"1407_CR44","first-page":"1028","volume":"29","author":"M Kostine","year":"2016","unstructured":"Kostine M, et al. Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. Mod Pathol Off J U S Can Acad Pathol Inc. 2016;29:1028\u201337.","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"1407_CR45","doi-asserted-by":"crossref","first-page":"100271","DOI":"10.1016\/j.jbo.2019.100271","volume":"20","author":"R Iseulys","year":"2020","unstructured":"Iseulys R, et al. The immune landscape of chondrosarcoma reveals an immunosuppressive environment in the dedifferentiated subtypes and exposes CSFR1\u2009+\u2009macrophages as a promising therapeutic target. J Bone Oncol. 2020;20:100271.","journal-title":"J Bone Oncol"},{"key":"1407_CR46","doi-asserted-by":"publisher","first-page":"30093","DOI":"10.1038\/srep30093","volume":"6","author":"P Koirala","year":"2016","unstructured":"Koirala P, et al. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep. 2016;6:30093.","journal-title":"Sci Rep"},{"key":"1407_CR47","doi-asserted-by":"publisher","first-page":"598001","DOI":"10.3389\/fonc.2021.598001","volume":"11","author":"SPFT Nota","year":"2021","unstructured":"Nota SPFT, et al. High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease. Front Oncol. 2021;11:598001.","journal-title":"Front Oncol"},{"key":"1407_CR48","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/jor.24463","volume":"38","author":"KM Amer","year":"2020","unstructured":"Amer KM, Munn M, Congiusta D, Abraham JA. Basu Mallick, A. Survival and Prognosis of Chondrosarcoma Subtypes: SEER Database Analysis. J Orthop Res Off Publ Orthop Res Soc. 2020;38:311\u20139.","journal-title":"J Orthop Res Off Publ Orthop Res Soc"},{"key":"1407_CR49","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/j.ejca.2007.06.016","volume":"43","author":"RJ Grimer","year":"2007","unstructured":"Grimer RJ, et al. Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. Eur J Cancer Oxf Engl. 2007;43:2060\u20135. (2007).","journal-title":"Eur J Cancer Oxf Engl"},{"key":"1407_CR50","doi-asserted-by":"crossref","unstructured":"Fiorenza F et al. Risk factors for survival and local control in chondrosarcoma of bone. J Bone Joint Surg Br. 2002;84.","DOI":"10.1302\/0301-620X.84B1.0840093"},{"key":"1407_CR51","doi-asserted-by":"crossref","unstructured":"Funovics PT et al. Low-grade chondrosarcoma of bone: experiences from the Vienna Bone and Soft Tissue Tumour Registry. Int Orthop. 2011;35.","DOI":"10.1007\/s00264-010-1065-x"},{"key":"1407_CR52","doi-asserted-by":"crossref","unstructured":"Sheth DS et al. Chondrosarcoma of the pelvis. Prognostic factors for 67 patients treated with definitive surgery. Cancer. 1996;78.","DOI":"10.1002\/(SICI)1097-0142(19960815)78:4<745::AID-CNCR9>3.0.CO;2-D"},{"key":"1407_CR53","doi-asserted-by":"crossref","unstructured":"Me P, Kl W, Kk U, Fh S. Chondrosarcoma of the pelvis. A review of sixty-four cases. J Bone Joint Surg Am. 2001;83.","DOI":"10.2106\/00004623-200111000-00003"},{"key":"1407_CR54","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1302\/0301-620X.82B1.0820055","volume":"82","author":"AD Mitchell","year":"2000","unstructured":"Mitchell AD, et al. Experience in the treatment of dedifferentiated chondrosarcoma. J Bone Joint Surg Br. 2000;82:55\u201361.","journal-title":"J Bone Joint Surg Br"},{"key":"1407_CR55","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.2217\/fon-2021-0830","volume":"17","author":"AK Kattepur","year":"2021","unstructured":"Kattepur AK, Jones RL, Gulia A. Dedifferentiated chondrosarcoma: current standards of care. Future Oncol. 2021;17:4983\u201391.","journal-title":"Future Oncol"},{"key":"1407_CR56","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.otsr.2009.05.004","volume":"95","author":"X Deloin","year":"2009","unstructured":"Deloin X, et al. Pelvic chondrosarcomas: surgical treatment options. Orthop Traumatol Surg Res OTSR. 2009;95:393\u2013401.","journal-title":"Orthop Traumatol Surg Res OTSR"},{"key":"1407_CR57","first-page":"1412","volume":"44","author":"JD Stevenson","year":"2018","unstructured":"Stevenson JD, et al. The role of surgical margins in chondrosarcoma. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2018;44:1412\u20138.","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"1407_CR58","first-page":"473","volume":"26","author":"A Sambri","year":"2021","unstructured":"Sambri A, Tuzzato G, Donati DM, De Paolis M, Bianchi G. Pathological fracture does not affect prognosis in dedifferentiated chondrosarcoma of the limbs. J Orthop Sci Off J Jpn Orthop Assoc. 2021;26:473\u20137.","journal-title":"J Orthop Sci Off J Jpn Orthop Assoc"},{"key":"1407_CR59","first-page":"36","volume":"4","author":"L Ollivier","year":"2003","unstructured":"Ollivier L, Vanel D, Lecl\u00e8re J. Imaging of chondrosarcomas. Cancer Imaging Off Publ Int Cancer Imaging Soc. 2003;4:36\u20138.","journal-title":"Cancer Imaging Off Publ Int Cancer Imaging Soc"},{"key":"1407_CR60","doi-asserted-by":"publisher","first-page":"440","DOI":"10.52312\/jdrs.2022.526","volume":"33","author":"HS Co\u015fkun","year":"2022","unstructured":"Co\u015fkun HS, Erdo\u011fan F, B\u00fcy\u00fckceran \u0130, Dabak N. Evaluation of prognostic factors affecting survival in chondrosarcoma treatment and comparison with literature. Jt Dis Relat Surg. 2022;33:440\u20138.","journal-title":"Jt Dis Relat Surg"},{"key":"1407_CR61","first-page":"836","volume":"110","author":"N Kremenevski","year":"2020","unstructured":"Kremenevski N, et al. Skull Base Chordomas Chondrosarcomas Neuroendocrinol. 2020;110:836\u201347.","journal-title":"Skull Base Chordomas Chondrosarcomas Neuroendocrinol"},{"key":"1407_CR62","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1002\/cncr.21936","volume":"106","author":"EL Staals","year":"2006","unstructured":"Staals EL, Bacchini P, Bertoni F. Dedifferentiated central chondrosarcoma. Cancer. 2006;106:2682\u201391.","journal-title":"Cancer"},{"key":"1407_CR63","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/jso.23617","volume":"110","author":"TF DeLaney","year":"2014","unstructured":"DeLaney TF, et al. Long-term results of Phase II study of high dose photon\/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas: Spine Sarcoma: Photon\/Proton Radiation. J Surg Oncol. 2014;110:115\u201322.","journal-title":"J Surg Oncol"},{"key":"1407_CR64","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S1470-2045(05)70282-5","volume":"6","author":"JVMG Bov\u00e9e","year":"2005","unstructured":"Bov\u00e9e JVMG, Cleton-Jansen A-M, Taminiau AHM, Hogendoorn P. C. W. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol. 2005;6:599\u2013607.","journal-title":"Lancet Oncol"},{"key":"1407_CR65","doi-asserted-by":"publisher","first-page":"e0173665","DOI":"10.1371\/journal.pone.0173665","volume":"12","author":"C Liu","year":"2017","unstructured":"Liu C, et al. Dedifferentiated chondrosarcoma: Radiological features, prognostic factors and survival statistics in 23 patients. PLoS ONE. 2017;12:e0173665.","journal-title":"PLoS ONE"},{"key":"1407_CR66","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.2106\/00004623-198668080-00008","volume":"68","author":"FJ Frassica","year":"1986","unstructured":"Frassica FJ, Unni KK, Beabout JW, Sim FH. Dedifferentiated chondrosarcoma. A report of the clinicopathological features and treatment of seventy-eight cases. J Bone Joint Surg Am. 1986;68:1197\u2013205.","journal-title":"J Bone Joint Surg Am"},{"key":"1407_CR67","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s11999-013-3360-5","volume":"472","author":"S Kawaguchi","year":"2014","unstructured":"Kawaguchi S, et al. Does ifosfamide therapy improve survival of patients with dedifferentiated chondrosarcoma? Clin Orthop. 2014;472:983\u20139.","journal-title":"Clin Orthop"},{"key":"1407_CR68","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ejca.2021.04.017","volume":"151","author":"I Hompland","year":"2021","unstructured":"Hompland I, et al. Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study. Eur J Cancer. 2021;151:150\u20138.","journal-title":"Eur J Cancer"},{"key":"1407_CR69","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13569-018-0110-1","volume":"8","author":"JR Lex","year":"2018","unstructured":"Lex JR, et al. Dedifferentiated chondrosarcoma of the pelvis: clinical outcomes and current treatment. Clin Sarcoma Res. 2018;8:23.","journal-title":"Clin Sarcoma Res"},{"key":"1407_CR70","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1634\/theoncologist.2017-0574","volume":"24","author":"A van Maldegem","year":"2019","unstructured":"van Maldegem A, et al. Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma. Oncologist. 2019;24:110\u20136.","journal-title":"Oncologist"},{"key":"1407_CR71","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1749-799X-7-38","volume":"7","author":"K Yokota","year":"2012","unstructured":"Yokota K, et al. Clinical outcome for patients with dedifferentiated chondrosarcoma: a report of 9 cases at a single institute. J Orthop Surg. 2012;7:38.","journal-title":"J Orthop Surg"},{"key":"1407_CR72","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1093\/annonc\/mdt374","volume":"24","author":"A Italiano","year":"2013","unstructured":"Italiano A, et al. Advanced chondrosarcomas: role of chemotherapy and survival. Ann Oncol Off J Eur Soc Med Oncol. 2013;24:2916\u201322.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"1407_CR73","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/CORR.0000000000002011","volume":"480","author":"LD Cranmer","year":"2022","unstructured":"Cranmer LD, et al. Is Chemotherapy Associated with Improved Overall Survival in Patients with Dedifferentiated Chondrosarcoma? A SEER Database Analysis. Clin Orthop. 2022;480:748\u201358.","journal-title":"Clin Orthop"},{"key":"1407_CR74","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.3390\/cancers15092617","volume":"15","author":"N Bui","year":"2023","unstructured":"Bui N, et al. A Retrospective Multi-Institutional Cohort Analysis of Clinical Characteristics and Outcomes in Dedifferentiated Chondrosarcoma. Cancers. 2023;15:2617.","journal-title":"Cancers"},{"key":"1407_CR75","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, et al. Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283\u201394.","journal-title":"Lancet Oncol"},{"key":"1407_CR76","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373:23\u201334.","journal-title":"N Engl J Med"},{"key":"1407_CR77","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","volume":"19","author":"MB Atkins","year":"2018","unstructured":"Atkins MB, et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 2018;19:405\u201315.","journal-title":"Lancet Oncol"},{"key":"1407_CR78","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","volume":"19","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo SP, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19:416\u201326.","journal-title":"Lancet Oncol"},{"key":"1407_CR79","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi HA, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18:1493\u2013501.","journal-title":"Lancet Oncol"},{"key":"1407_CR80","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2303383","volume":"389","author":"AP Chen","year":"2023","unstructured":"Chen AP, et al. Atezolizumab for Advanced Alveolar Soft Part Sarcoma. N Engl J Med. 2023;389:911\u201321.","journal-title":"N Engl J Med"},{"key":"1407_CR81","doi-asserted-by":"publisher","first-page":"e002990","DOI":"10.1136\/jitc-2021-002990","volume":"9","author":"MJ Wagner","year":"2021","unstructured":"Wagner MJ, et al. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). J Immunother Cancer. 2021;9:e002990.","journal-title":"J Immunother Cancer"},{"key":"1407_CR82","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2217\/imt-2023-0110","volume":"15","author":"T Assi","year":"2023","unstructured":"Assi T, Ibrahim R, Ibrahim T, Khoury R, Cesne AL. Ipilimumab and nivolumab: the \u2018new kid on the block\u2019 in advanced angiosarcoma. Immunotherapy. 2023;15:1089\u201391.","journal-title":"Immunotherapy"},{"key":"1407_CR83","doi-asserted-by":"publisher","first-page":"991724","DOI":"10.3389\/fonc.2022.991724","volume":"12","author":"A Singh","year":"2022","unstructured":"Singh A, Thorpe SW, Darrow M, Carr-Ascher JR. Case report: Treatment of metastatic dedifferentiated chondrosarcoma with pembrolizumab yields sustained complete response. Front Oncol. 2022;12:991724.","journal-title":"Front Oncol"},{"key":"1407_CR84","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13569-016-0064-0","volume":"6","author":"L Paoluzzi","year":"2016","unstructured":"Paoluzzi L, et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res. 2016;6:24.","journal-title":"Clin Sarcoma Res"},{"key":"1407_CR85","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41392-025-02173-3","volume":"10","author":"A Levy","year":"2025","unstructured":"Levy A, et al. Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results. Signal Transduct Target Ther. 2025;10:103.","journal-title":"Signal Transduct Target Ther"},{"key":"1407_CR86","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/cncr.32515","volume":"126","author":"W Chow","year":"2020","unstructured":"Chow W, et al. Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma. Cancer. 2020;126:105\u201311.","journal-title":"Cancer"},{"key":"1407_CR87","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/S1470-2045(19)30319-5","volume":"20","author":"S Stacchiotti","year":"2019","unstructured":"Stacchiotti S, et al. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2019;20:1252\u201362.","journal-title":"Lancet Oncol"},{"key":"1407_CR88","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2021.03.039","volume":"150","author":"F Duffaud","year":"2021","unstructured":"Duffaud F, et al. Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. Eur J Cancer. 2021;150:108\u201318.","journal-title":"Eur J Cancer"},{"key":"1407_CR89","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/cncr.25632","volume":"117","author":"G Grignani","year":"2011","unstructured":"Grignani G, et al. A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-\u03b1 or -\u03b2: An Italian Sarcoma Group study. Cancer. 2011;117:826\u201331.","journal-title":"Cancer"},{"key":"1407_CR90","doi-asserted-by":"publisher","first-page":"6216","DOI":"10.1158\/0008-5472.CAN-08-4801","volume":"69","author":"YM Schrage","year":"2009","unstructured":"Schrage YM, et al. Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res. 2009;69:6216\u201322.","journal-title":"Cancer Res"},{"key":"1407_CR91","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/cncr.30379","volume":"123","author":"SM Schuetze","year":"2017","unstructured":"Schuetze SM, et al. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. Cancer. 2017;123:90\u20137.","journal-title":"Cancer"},{"key":"1407_CR92","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1158\/1078-0432.CCR-12-3647","volume":"19","author":"Y-X Zhang","year":"2013","unstructured":"Zhang Y-X, et al. Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19:3796\u2013807.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1407_CR93","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","volume":"26","author":"X Wan","year":"2007","unstructured":"Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2007;26:1932\u201340.","journal-title":"Oncogene"},{"key":"1407_CR94","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1158\/1078-0432.CCR-23-0974","volume":"29","author":"V Subbiah","year":"2023","unstructured":"Subbiah V, et al. Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma. Clin Cancer Res. 2023;29:2988\u20133003.","journal-title":"Clin Cancer Res"},{"key":"1407_CR95","doi-asserted-by":"publisher","unstructured":"The tetravalent death receptor 5 (DR5.) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.11504","DOI":"10.1200\/JCO.2026.44.16_suppl.11504"},{"key":"1407_CR96","doi-asserted-by":"publisher","first-page":"e0133813","DOI":"10.1371\/journal.pone.0133813","volume":"10","author":"L Li","year":"2015","unstructured":"Li L, et al. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells. PLoS ONE. 2015;10:e0133813.","journal-title":"PLoS ONE"},{"key":"1407_CR97","doi-asserted-by":"publisher","first-page":"105090","DOI":"10.1016\/j.ebiom.2024.105090","volume":"102","author":"V Rey","year":"2024","unstructured":"Rey V, et al. A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma. EBioMedicine. 2024;102:105090.","journal-title":"EBioMedicine"},{"key":"1407_CR98","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1200\/JCO.19.02492","volume":"38","author":"WD Tap","year":"2020","unstructured":"Tap WD, et al. Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38:1693\u2013701.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1407_CR99","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nri3064","volume":"11","author":"GT Motz","year":"2011","unstructured":"Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol. 2011;11:702\u201311.","journal-title":"Nat Rev Immunol"},{"key":"1407_CR100","doi-asserted-by":"publisher","first-page":"11506","DOI":"10.1200\/JCO.2024.42.16_suppl.11506","volume":"42","author":"SJ Strauss","year":"2024","unstructured":"Strauss SJ, et al. ImmunoSarc II master trial (phase II of sunitinib and nivolumab): Results from the dedifferentiated chondrosarcoma (DDCS) cohort\u2014A GEIS, ISG and UCL study. J Clin Oncol. 2024;42:11506\u201311506.","journal-title":"J Clin Oncol"},{"key":"1407_CR101","doi-asserted-by":"publisher","first-page":"100809","DOI":"10.1016\/j.medj.2025.100809","volume":"6","author":"B Li","year":"2025","unstructured":"Li B, et al. Anti-PD-1 antibody plus anlotinib vs. anlotinib alone in patients with refractory chondrosarcoma: A multicenter, non-randomized phase 2 FLAIL-C trial. Med. 2025;6:100809.","journal-title":"Med"},{"key":"1407_CR102","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff IK, et al. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med. 2023;389:589\u2013601.","journal-title":"N Engl J Med"},{"key":"1407_CR103","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1021\/acsmedchemlett.9b00509","volume":"11","author":"Z Konteatis","year":"2020","unstructured":"Konteatis Z, et al. Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma. ACS Med Chem Lett. 2020;11:101\u20137.","journal-title":"ACS Med Chem Lett"},{"key":"1407_CR104","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1126\/science.aad5944","volume":"351","author":"KJ Mavrakis","year":"2016","unstructured":"Mavrakis KJ, et al. Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5. Science. 2016;351:1208\u201313.","journal-title":"Science"},{"key":"1407_CR105","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","volume":"35","author":"J Rodon","year":"2024","unstructured":"Rodon J, et al. First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration. Ann Oncol. 2024;35:1138\u201347.","journal-title":"Ann Oncol"},{"key":"1407_CR106","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s13577-018-00232-2","volume":"32","author":"R Oyama","year":"2019","unstructured":"Oyama R, et al. Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line, NCC-dCS1-C1. Hum Cell. 2019;32:202\u201313.","journal-title":"Hum Cell"},{"key":"1407_CR107","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s13577-023-00944-0","volume":"36","author":"M Emori","year":"2023","unstructured":"Emori M, et al. Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line, SMU-DDCS, harboring an IDH1 mutation. Hum Cell. 2023;36:2195\u2013203.","journal-title":"Hum Cell"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01407-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-026-01407-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01407-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:11:51Z","timestamp":1785521511000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-026-01407-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":107,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1407"],"URL":"https:\/\/doi.org\/10.1007\/s11864-026-01407-y","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"5 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"41"}}